Endocrine therapy use among elderly hormone receptor-positive breast cancer patients enrolled in Medicare Part D.

Medicare & Medicaid Research Review
Gerald F RileySteven A Blackwell

Abstract

Clinical guidelines recommend that women with hormone-receptor positive breast cancer receive endocrine therapy (selective estrogen receptor modulators [SERMs] or aromatase inhibitors [AIs]) for five years following diagnosis. To examine utilization and adherence to therapy for SERMs and AIs in Medicare Part D prescription drug plans. Linked Surveillance, Epidemiology, and End Results (SEER)-Medicare data. We identified 15,542 elderly women diagnosed with hormone-receptor positive breast cancer in years 2003-2005 (the latest SEER data at the time of the study) and enrolled in a Part D plan in 2006 or 2007 (the initial years of Part D). This permitted us to compare utilization and adherence to therapy at various points within the recommended five-year timeframe for endocrine therapy. SERM and AI use was measured from claim records. Non-adherence to therapy was defined as a medication possession ratio of less than 80 percent. Between May 2006 and December 2007, 22 percent of beneficiaries received SERM, 52 percent AI, and 26 percent received neither. The percent receiving any endocrine therapy decreased with time from diagnosis. Among SERM and AI users, 20-30 percent were non-adherent to therapy; out-of-pocket costs wer...Continue Reading

References

Feb 15, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ann H PartridgeJerry Avorn
Dec 31, 2005·The New England Journal of Medicine·Rachel A ElliottStephen B Soumerai
Dec 31, 2005·The New England Journal of Medicine·UNKNOWN Breast International Group (BIG) 1-98 Collaborative GroupAron Goldhirsch
Feb 18, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Linda C HarlanRachel Ballard-Barbash
Mar 17, 2006·Breast Cancer Research and Treatment·Timothy L LashRebecca A Silliman
Mar 9, 2007·Oncology·Rowan T Chlebowski, Michelle L Geller
Mar 30, 2007·Breast Cancer Research and Treatment·Erin J AielloAnn M Geiger
Jul 5, 2007·JAMA : the Journal of the American Medical Association·Dana P GoldmanYuhui Zheng
Dec 12, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Cynthia OwusuRebecca A Silliman
Jan 9, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ann H PartridgeAviva Asnis-Alibozek
Mar 21, 2009·Critical Reviews in Oncology/hematology·Peyman Hadji
May 20, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gretchen KimmickRajesh Balkrishnan
Nov 6, 2009·Health Affairs·Gerald F RileyMelissa A Montgomery
Apr 22, 2010·Journal of the American Geriatrics Society·Jennifer M PolinskiWilliam H Shrank
Jun 30, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Dawn L HershmanAlfred I Neugut
Sep 25, 2010·Journal of the American Geriatrics Society·Jennifer M PolinskiWilliam H Shrank
Nov 3, 2010·Health Affairs·Niteesh K ChoudhryWilliam H Shrank
Nov 3, 2010·Health Affairs·Matthew L MaciejewskiDaryl Wansink

❮ Previous
Next ❯

Citations

Aug 29, 2014·Breast Cancer Research and Treatment·Lu ChenChristopher I Li
Jun 13, 2012·Breast Cancer Research and Treatment·Caitlin C MurphySally W Vernon
Apr 24, 2015·American Journal of Public Health·Megan C RobertsKatherine Reeder-Hayes
Apr 30, 2016·Pharmacoepidemiology and Drug Safety·Aaron N Winn, Stacie B Dusetzina
May 3, 2016·Journal of Geriatric Oncology·Brittany L Bychkovsky, Mara A Schonberg
Aug 20, 2016·Expert Opinion on Pharmacotherapy·Katarzyna J JerzakKathleen I Pritchard
Jun 18, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Vanessa B SheppardJeanne S Mandelblatt
May 15, 2015·Journal of the National Cancer Institute·Joan M NeunerLiliana E Pezzin
Dec 16, 2017·Journal of Cancer Survivorship : Research and Practice·Joan M NeunerJohn A Charlson
Sep 5, 2015·Clinical Medicine Insights. Oncology·David Riseberg
Jan 2, 2018·Journal of Managed Care & Specialty Pharmacy·Min Jee LeeRamzi G Salloum
Nov 6, 2018·Breast Cancer Research and Treatment·Sue P HeineyJennifer M Hulett
Jul 2, 2015·Medicine·Xi TanRajesh Balkrishnan
Apr 7, 2020·American Journal of Clinical Oncology·Sue P HeineySwann Arp Adams
Dec 22, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alana BiggersJoan M Neuner
Sep 9, 2017·Breast Cancer Research and Treatment·Marie S DreyerLiliana E Pezzin
Dec 31, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Albert J Farias, Xianglin L Du
Mar 28, 2018·BioMed Research International·Suk-Young Lee, Jae Hong Seo
Sep 14, 2020·Breast Cancer Research and Treatment·Max O MeneveauShayna L Showalter
Jan 21, 2014·Cancer Prevention Research·Rowan T ChlebowskiReina Haque
Jun 3, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Rachel A Freedman, Ann H Partridge

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Expert Opinion on Pharmacotherapy
Jennifer Keating LittonGabriel N Hortobagyi
Journal of the Society for Gynecologic Investigation
V Craig Jordan
The Breast : Official Journal of the European Society of Mastology
Eva CiruelosHernán Cortes-Funes
© 2022 Meta ULC. All rights reserved